Definium Therapeutics (DFTX) Common Equity (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Common Equity data on file, last reported at $278.8 million in Q1 2026.

• Quarterly Common Equity rose 25.15% year-over-year to $278.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278.8 million (up 25.15% YoY) and the FY2025 annual result came in at $332.3 million, up 37.64% from the prior year.
• Common Equity slipped to $278.8 million in Q1 2026 per DFTX's latest filing, from $332.3 million in the prior quarter.
• Across five years, Common Equity topped out at $332.3 million in Q4 2025 and bottomed at $78.1 million in Q4 2023.
• The 5-year median for Common Equity is $153.6 million (2022), against an average of $178.1 million.
• The widest annual swing landed in 2024, when Common Equity soared 209.02%; it then tumbled 50.19% in 2025.
• Tracing DFTX's Common Equity over 5 years: stood at $150.9 million in 2022, then tumbled by 48.23% to $78.1 million in 2023, then soared by 209.02% to $241.4 million in 2024, then jumped by 37.64% to $332.3 million in 2025, then retreated by 16.09% to $278.8 million in 2026.
• Per Business Quant, the three latest DFTX Common Equity figures stand at $278.8 million (Q1 2026), $332.3 million (Q4 2025), and $130.6 million (Q3 2025).

Peer Comparison